EXPLORENCT06945224
A ReaL World Study of DS-8201
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗
- Notable Primary completion date changed from estimate of Jun 30, 2025 to Apr 1, 2026
- Start date: Dec 1, 2024 to Apr 19, 2025
- Eligibility criteria expanded, about 14 words
- Study completion pushed from Jun 30, 2025 to Nov 2026
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
PFS
Timeframe: Six months after the last patient was enrolled
Arms and interventions
Patients received DS-8201
HER2-positive and HER2-low breast cancer patients who received DS-8201 in the advanced stage
Sites
1 site in 1 country
- Fudan University Shanghai Cancer centerShanghai, China, China